levomepromazine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	1752	60-99-1

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: methotrimeprazine hirnamin levomeprazine levomepromazin levopromazine levoprome levopromethazine levotomin mepromazine levomepromazine levomepromazine maleate methotrimeprazine hydrochloride nozinan	A phenothiazine with pharmacological activity similar to that of both CHLORPROMAZINE and PROMETHAZINE. It has the histamine-antagonist properties of the antihistamines together with CENTRAL NERVOUS SYSTEM effects resembling those of chlorpromazine. (From Martindale, The Extra Pharmacopoeia, 30th ed, p604) Molecular weight: 328.47 Formula: C19H24N2OS CLOGP: 5.03 LIPINSKI: 1 HAC: 3 HDO: 0 TPSA: 15.71 ALOGS: -4.80 ROTB: 5 Status: OFM Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

methotrimeprazine
hirnamin
levomeprazine
levomepromazin
levopromazine
levoprome
levopromethazine
levotomin
mepromazine
levomepromazine
levomepromazine maleate
methotrimeprazine hydrochloride
nozinan

A phenothiazine with pharmacological activity similar to that of both CHLORPROMAZINE and PROMETHAZINE. It has the histamine-antagonist properties of the antihistamines together with CENTRAL NERVOUS SYSTEM effects resembling those of chlorpromazine. (From Martindale, The Extra Pharmacopoeia, 30th ed, p604)

Molecular weight: 328.47
Formula: C19H24N2OS
CLOGP: 5.03
LIPINSKI: 1
HAC: 3
HDO: 0
TPSA: 15.71
ALOGS: -4.80
ROTB: 5

Status: OFM

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
0.30	g	O
0.10	g	P

ADMET properties:

Property	Value	Reference
BA (Bioavailability)	50 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	12 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	9.90 mL/min/kg	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	30 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
None	FDA	IMMUNEX

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Intentional overdose	221.70	23.16	118	5637	62386	50536983
Intentional self-injury	146.49	23.16	65	5690	23047	50576322
Drug interaction	129.49	23.16	135	5620	199486	50399883
Somnolence	128.72	23.16	120	5635	154865	50444504
Toxicity to various agents	120.75	23.16	134	5621	212365	50387004
Extrapyramidal disorder	97.36	23.16	40	5715	11730	50587639
Electrocardiogram QT prolonged	87.65	23.16	61	5694	51825	50547544
Urinary retention	80.32	23.16	45	5710	26145	50573224
Excessive eye blinking	79.44	23.16	19	5736	927	50598442
Neuroleptic malignant syndrome	79.24	23.16	34	5721	11096	50588273
Sopor	63.24	23.16	35	5720	19844	50579525
Suicide attempt	54.63	23.16	46	5709	51686	50547683
Altered state of consciousness	52.26	23.16	32	5723	21878	50577491
Depressed level of consciousness	48.38	23.16	43	5712	51910	50547459
Product use in unapproved indication	44.34	23.16	60	5695	115759	50483610
Drug abuse	41.35	23.16	42	5713	59804	50539565
Hallucination, auditory	40.01	23.16	21	5734	10707	50588662
Aggression	36.02	23.16	25	5730	21091	50578278
Vascular pain	33.86	23.16	9	5746	674	50598695
Asphyxia	33.50	23.16	15	5740	5412	50593957
Hyperprolactinaemia	33.23	23.16	13	5742	3352	50596017
Mental disorder	32.82	23.16	24	5731	21967	50577402
Psychiatric symptom	32.65	23.16	14	5741	4556	50594813
Hypothermia	32.41	23.16	19	5736	11997	50587372
Tension	32.04	23.16	12	5743	2750	50596619
Overdose	31.27	23.16	47	5708	99680	50499689
Illusion	30.83	23.16	9	5746	950	50598419
Diabetic hyperosmolar coma	28.86	23.16	7	5748	362	50599007
Flat affect	28.10	23.16	9	5746	1296	50598073
Bradykinesia	27.90	23.16	12	5743	3931	50595438
Disinhibition	27.81	23.16	8	5747	802	50598567
Muscle rigidity	27.72	23.16	16	5739	9813	50589556
Pulmonary embolism	26.45	23.16	44	5711	101660	50497709
Perforation	26.44	23.16	8	5747	956	50598413
Behaviour disorder	26.37	23.16	10	5745	2370	50596999
Psychomotor retardation	26.17	23.16	11	5744	3407	50595962
Depressed mood	25.55	23.16	25	5730	33998	50565371
Disturbance in attention	25.47	23.16	24	5731	31162	50568207
Galactorrhoea	25.26	23.16	11	5744	3712	50595657
Partial seizures with secondary generalisation	24.56	23.16	6	5749	320	50599049
Blood prolactin increased	23.82	23.16	10	5745	3089	50596280
Antipsychotic drug level increased	23.78	23.16	10	5745	3099	50596270
Schizophrenia	23.45	23.16	13	5742	7384	50591985

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Neuroleptic malignant syndrome	140.60	25.42	67	5769	16081	29552610
Drug abuse	132.16	25.42	116	5720	79767	29488924
Intentional self-injury	106.30	25.42	51	5785	12410	29556281
Sopor	82.01	25.42	41	5795	10893	29557798
Toxicity to various agents	79.75	25.42	131	5705	173530	29395161
Extrapyramidal disorder	76.51	25.42	39	5797	10792	29557899
Dystonic tremor	74.39	25.42	15	5821	182	29568509
Acute pulmonary oedema	67.85	25.42	31	5805	6748	29561943
Suicide attempt	67.47	25.42	55	5781	34055	29534636
Blood glucose fluctuation	57.75	25.42	23	5813	3574	29565117
Intestinal haemorrhage	57.61	25.42	22	5814	3057	29565634
Dystonia	57.17	25.42	31	5805	9718	29558973
Intentional overdose	53.83	25.42	51	5785	38477	29530214
Electrocardiogram QT prolonged	48.90	25.42	47	5789	36090	29532601
Wrong patient received product	48.86	25.42	18	5818	2264	29566427
Altered state of consciousness	47.80	25.42	36	5800	19853	29548838
Blood glucose abnormal	46.98	25.42	22	5814	5061	29563630
Restlessness	46.50	25.42	37	5799	22108	29546583
Sudden death	44.16	25.42	30	5806	14080	29554611
Drug interaction	43.59	25.42	110	5726	197275	29371416
Cognitive disorder	42.50	25.42	36	5800	23463	29545228
Parkinsonism	42.27	25.42	23	5813	7255	29561436
Victim of chemical submission	38.43	25.42	7	5829	47	29568644
Gastrointestinal hypermotility	38.03	25.42	8	5828	121	29568570
Rhabdomyolysis	37.87	25.42	53	5783	60755	29507936
Somnolence	37.82	25.42	67	5769	93888	29474803
Blood creatine phosphokinase increased	37.33	25.42	43	5793	40601	29528090
Electrocardiogram QT shortened	36.88	25.42	8	5828	141	29568550
Wrong schedule	36.67	25.42	8	5828	145	29568546
Aggression	33.31	25.42	38	5798	35503	29533188
Drug screen false positive	33.25	25.42	10	5826	670	29568021
Dyspnoea	32.54	25.42	12	5824	326720	29241971
Respiratory depression	31.42	25.42	24	5812	13499	29555192
Urinary incontinence	31.34	25.42	26	5810	16455	29552236
Overdose	30.92	25.42	56	5780	79763	29488928
Schizophrenia	30.69	25.42	18	5818	6547	29562144
Mumps	29.16	25.42	6	5830	81	29568610
Depressed level of consciousness	28.85	25.42	36	5800	36906	29531785
Product administration error	28.10	25.42	23	5813	14287	29554404
Miosis	27.39	25.42	18	5818	7991	29560700
Feelings of worthlessness	27.28	25.42	7	5829	260	29568431
Confusional state	26.83	25.42	70	5766	127807	29440884
Balance disorder	26.27	25.42	34	5802	36136	29532555
Hyperhidrosis	25.91	25.42	46	5790	64494	29504197
Coma	25.46	25.42	35	5801	39415	29529276

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Neuroleptic malignant syndrome	213.81	20.09	98	10912	24898	64462824
Intentional overdose	178.87	20.09	137	10873	89807	64397915
Intentional self-injury	158.95	20.09	84	10926	28960	64458762
Extrapyramidal disorder	155.78	20.09	73	10937	19479	64468243
Toxicity to various agents	142.70	20.09	236	10774	363277	64124445
Drug abuse	142.25	20.09	142	10868	132232	64355490
Somnolence	140.26	20.09	173	10837	203472	64284250
Sopor	132.45	20.09	75	10935	29586	64458136
Drug interaction	123.55	20.09	221	10789	361862	64125860
Suicide attempt	117.19	20.09	97	10913	70910	64416812
Electrocardiogram QT prolonged	96.06	20.09	91	10919	79357	64408365
Altered state of consciousness	89.29	20.09	64	10946	37838	64449884
Dystonic tremor	76.55	20.09	15	10995	182	64487540
Aggression	65.69	20.09	58	10952	46174	64441548
Depressed level of consciousness	63.80	20.09	74	10936	81362	64406360
Wrong patient received product	59.97	20.09	23	10987	3739	64483983
Psychiatric symptom	58.03	20.09	26	10984	6247	64481475
Excessive eye blinking	57.52	20.09	17	10993	1243	64486479
Dystonia	51.77	20.09	35	10975	18830	64468892
Acute pulmonary oedema	50.79	20.09	30	10980	12779	64474943
Restlessness	50.79	20.09	47	10963	39738	64447984
Overdose	49.88	20.09	94	10916	159472	64328250
Sudden death	49.77	20.09	35	10975	20061	64467661
Urinary retention	45.90	20.09	49	10961	49152	64438570
Psychomotor hyperactivity	44.97	20.09	29	10981	14422	64473300
Muscle rigidity	42.27	20.09	30	10980	17443	64470279
Blood creatine phosphokinase increased	42.19	20.09	51	10959	58507	64429215
Schizophrenia	41.27	20.09	25	10985	11143	64476579
Substance abuse	40.11	20.09	23	10987	9269	64478453
Rhabdomyolysis	39.08	20.09	62	10948	91664	64396058
Intestinal haemorrhage	39.05	20.09	19	10991	5495	64482227
Hypothermia	38.84	20.09	30	10980	19826	64467896
Parkinsonism	37.85	20.09	26	10984	14347	64473375
Salivary hypersecretion	34.50	20.09	23	10987	12090	64475632
Agitation	33.94	20.09	57	10953	88310	64399412
Akathisia	33.13	20.09	22	10988	11488	64476234
Wrong schedule	31.90	20.09	8	11002	314	64487408
Coma	31.65	20.09	55	10955	87560	64400162
Depressed mood	31.64	20.09	37	10973	40975	64446747
Drug screen false positive	30.76	20.09	10	11000	1002	64486720
Cognitive disorder	28.82	20.09	41	10969	55046	64432676
Vascular pain	28.55	20.09	9	11001	817	64486905
Sedation	28.06	20.09	35	10975	41427	64446295
Behaviour disorder	27.53	20.09	14	10996	4448	64483274
Asphyxia	26.85	20.09	18	10992	9548	64478174
Blood glucose fluctuation	26.40	20.09	15	10995	5940	64481782
Rash	26.04	20.09	24	10986	458525	64029197
Mental disorder	25.83	20.09	27	10983	26418	64461304
Hyperprolactinaemia	25.80	20.09	13	10997	4052	64483670
Colitis ischaemic	25.65	20.09	20	10990	13394	64474328
Blood glucose abnormal	25.56	20.09	17	10993	8896	64478826
Product use in unapproved indication	25.45	20.09	77	10933	176541	64311181
Pain	24.89	20.09	35	10975	553476	63934246
Feelings of worthlessness	24.13	20.09	7	11003	479	64487243
Hallucination	24.11	20.09	44	10966	72744	64414978
Pneumonia aspiration	23.78	20.09	39	10971	59232	64428490
Abnormal behaviour	23.74	20.09	29	10981	33593	64454129
Obsessive-compulsive disorder	23.72	20.09	13	10997	4805	64482917
Disturbance in attention	23.62	20.09	32	10978	41042	64446680
Asthenia	23.60	20.09	23	10987	428021	64059701
Tension	23.55	20.09	12	10998	3828	64483894
Poisoning deliberate	23.45	20.09	19	10991	13439	64474283
Neuroleptic-induced deficit syndrome	23.07	20.09	4	11006	23	64487699
Illusion	22.90	20.09	9	11001	1561	64486161
Victim of chemical submission	22.63	20.09	6	11004	294	64487428
Galactorrhoea	22.52	20.09	11	10999	3208	64484514
Bradykinesia	22.49	20.09	14	10996	6546	64481176
Mania	22.26	20.09	20	10990	16266	64471456
Cough	22.15	20.09	12	10998	302136	64185586
Perforation	21.87	20.09	8	11002	1140	64486582
Ileus paralytic	21.63	20.09	15	10995	8400	64479322
Confusional state	21.58	20.09	95	10915	261049	64226673
Diabetic hyperosmolar coma	21.46	20.09	7	11003	709	64487013
Flat affect	21.44	20.09	9	11001	1848	64485874
Hyperhidrosis	21.42	20.09	58	10952	124862	64362860
Respiratory depression	21.24	20.09	23	10987	23420	64464302
Arthralgia	20.84	20.09	27	10983	442233	64045489
Chemical poisoning	20.81	20.09	5	11005	164	64487558
Dyskinesia	20.14	20.09	29	10981	39359	64448363

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	N05AA02	NERVOUS SYSTEM PSYCHOLEPTICS ANTIPSYCHOTICS Phenothiazines with aliphatic side-chain
MeSH PA	D000700	Analgesics
MeSH PA	D018712	Analgesics, Non-Narcotic
MeSH PA	D014150	Antipsychotic Agents
MeSH PA	D002491	Central Nervous System Agents
MeSH PA	D002492	Central Nervous System Depressants
MeSH PA	D015259	Dopamine Agents
MeSH PA	D018492	Dopamine Antagonists
MeSH PA	D018377	Neurotransmitter Agents
MeSH PA	D018373	Peripheral Nervous System Agents
MeSH PA	D011619	Psychotropic Drugs
MeSH PA	D018689	Sensory System Agents
MeSH PA	D014149	Tranquilizing Agents
CHEBI has role	CHEBI:37930	phenothiazine antipsychotic drugs
CHEBI has role	CHEBI:48279	serotonin antagonists
CHEBI has role	CHEBI:48561	dopaminergic antagonists
CHEBI has role	CHEBI:48873	acetylcholine receptor antagonist
CHEBI has role	CHEBI:76779	post-proline endopeptidase inhibitors
CHEBI has role	CHEBI:149553	anticoronaviral drug

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Alcoholism	contraindication	7200002
Organophosphate poisoning	contraindication	8260003
Weight gain finding	contraindication	8943002
Neuroleptic malignant syndrome	contraindication	15244003	DOID:14464
Senile dementia	contraindication	15662003
Chronic disease of respiratory system	contraindication	17097001
Myocardial infarction	contraindication	22298006	DOID:5844
Glaucoma	contraindication	23986001	DOID:1686
Orthostatic hypotension	contraindication	28651003
Torsades de pointes	contraindication	31722008
Parkinsonism	contraindication	32798002
Conduction disorder of the heart	contraindication	44808001
Chronic heart failure	contraindication	48447003
Bradycardia	contraindication	48867003
Extrapyramidal disease	contraindication	76349003
Hyperglycemia	contraindication	80394007	DOID:4195
Epilepsy	contraindication	84757009	DOID:1826
Leukopenia	contraindication	84828003	DOID:615
Stupor	contraindication	89458003
Tardive dyskinesia	contraindication	102449007
Prolonged QT interval	contraindication	111975006
Acute disease of cardiovascular system	contraindication	128487001
Angina pectoris	contraindication	194828000
Disease of liver	contraindication	235856003	DOID:409
Metabolic syndrome X	contraindication	237602007	DOID:14221
Hyperprolactinemia	contraindication	237662005	DOID:12700
Benign prostatic hyperplasia	contraindication	266569009
Retention of urine	contraindication	267064002
Anemia	contraindication	271737000	DOID:2355
Thrombocytopenic disorder	contraindication	302215000	DOID:1588
Neutropenic disorder	contraindication	303011007	DOID:1227
Coma	contraindication	371632003
At risk for aspiration	contraindication	371736008
Visual impairment	contraindication	397540003
Breastfeeding (mother)	contraindication	413712001
Myocardial ischemia	contraindication	414795007	DOID:3393
Obesity	contraindication	414916001	DOID:9970
Congenital long QT syndrome	contraindication	442917000
Carcinoma of female breast	contraindication	447782002

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	8.92	Basic
pKa2	4.55	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Histamine H1 receptor	GPCR	P35367	HRH1_HUMAN		Ki	9.24		PDSP
Pleiotropic ABC efflux transporter of multiple drugs	Transporter		PDR5_YEAST		IC50	5.02		CHEMBL

External reference:

ID	Source
4018915	VUID
N0000147208	NUI
D00403	KEGG_DRUG
4018915	VANDF
CHEBI:6838	CHEBI
CHEMBL1764	ChEMBL_ID
C017901	MESH_SUPPLEMENTAL_RECORD_UI
7603	IUPHAR_LIGAND_ID
705	INN_ID
7104-38-3	SECONDARY_CAS_RN
DB01403	DRUGBANK_ID
9G0LAW7ATQ	UNII
72287	PUBCHEM_CID
160372	RXNORM
1834	MMSL
5078	MMSL
d00814	MMSL
001581	NDDF
004134	NDDF
005070	NDDF
387509007	SNOMEDCT_US
395790003	SNOMEDCT_US
57911003	SNOMEDCT_US
89029005	SNOMEDCT_US
D008728	MESH_DESCRIPTOR_UI
C0025678	UMLSCUI
CHEMBL1725730	ChEMBL_ID
CHEMBL2104973	ChEMBL_ID

Pharmaceutical products:

None